Disease · MONDO_0013730
Comparisons in its trials58
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 58
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Incidence Rate of aGVHD Flares | 42 of 219 | 48 of 220 | 439 | NCT03139604 | Trial comparisons |
| Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Incidence Rate of Secondary Graft Failure | 2 of 219 | 0 of 220 | 439 | NCT03139604 | Trial comparisons |
| Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Number of Treatment-emergent Adverse Events With INCB39110 | 208 of 215 | 214 of 216 | 431 | NCT03139604 | Trial comparisons |
| PTCY/Tacrolimus/MMF vs Tacrolimus/Methotrexate: deaths from any cause | 58 of 214 | 70 of 217 | 431 | NCT03959241 | Trial comparisons |
| PTCY/Tacrolimus/MMF vs Tacrolimus/Methotrexate: serious adverse events | 7 of 208 | 14 of 212 | 420 | NCT03959241 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Incidence of Systemic Infections | 81 of 116 | 77 of 119 | 235 | NCT01002742 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Incidence of Epstein-Barr Virus (EBV)-Associated Lymphoma | 6 of 116 | 4 of 119 | 235 | NCT01002742 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Incidence of Topical/Non-absorbable Therapy | 77 of 116 | 81 of 119 | 235 | NCT01002742 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Incidence of GVHD Flares Requiring Increased Therapy | 8 of 116 | 16 of 119 | 235 | NCT01002742 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: serious adverse events | 13 of 116 | 13 of 119 | 235 | NCT01002742 | Trial comparisons |
| BPX-501 vs Rimiducid: deaths from any cause | 7 of 171 | 0 of 16 | 187 | NCT02065869 | Trial comparisons |
| BPX-501 vs Rimiducid: serious adverse events | 52 of 171 | 7 of 16 | 187 | NCT02065869 | Trial comparisons |
| Arm I (Low-dose) vs Arm II (Standard-dose): serious adverse events | 38 of 81 | 30 of 83 | 164 | NCT00929695 | Trial comparisons |
| Active vs Placebo: serious adverse events | 32 of 70 | 28 of 70 | 140 | NCT00926575 | Trial comparisons |
| Sirolimus, Calcineurin Inhibitor, and Prednisone vs Sirolimus and Prednisone: deaths from any cause | 16 of 66 | 13 of 72 | 138 | NCT01106833 | Trial comparisons |
| Sirolimus, Calcineurin Inhibitor, and Prednisone vs Sirolimus and Prednisone: serious adverse events | 13 of 66 | 12 of 72 | 138 | NCT01106833 | Trial comparisons |
| Alpha-1 Antitrypsin (AAT) vs Placebo: Number of Participants With GVHD-free Survival | 29 of 65 | 25 of 71 | 136 | NCT04167514 | Trial comparisons |
| Alpha-1 Antitrypsin (AAT) vs Placebo: deaths from any cause | 21 of 65 | 23 of 71 | 136 | NCT04167514 | Trial comparisons |
| Alpha-1 Antitrypsin (AAT) vs Placebo: serious adverse events | 11 of 63 | 23 of 69 | 132 | NCT04167514 | Trial comparisons |
| Flu-TBI vs TLI-ATG: Number of Participants With Graft Rejection as Defined by Whole Blood and T Cell Chimerism | 3 of 49 | 4 of 45 | 94 | NCT00603954 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013730/comparisons